{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:30:19Z","timestamp":1778873419676,"version":"3.51.4"},"reference-count":35,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T00:00:00Z","timestamp":1613260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The treatment of multiple myeloma (MM) has advanced with the introduction of immunomodulators (IMiDS). Thalidomide is the IMiD available in Brazil with free access to MM patients. Adherence to treatment with IMiDs is essential for a successful therapy. The study proposed to describe adherence to thalidomide treatment in patients diagnosed with MM in onco-hematological outpatient clinics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a cross-sectional study with patients over 18 years of age diagnosed with MM undergoing thalidomide treatment. Adherence was measured by the Proportion of Days Covered (PDC), which is an indirect method of measuring adherence that uses database-related medication dispensing information. Patients with PDC \u226590 were classified as adherent. The association between adherence and independent variables was assessed in univariate and multivariate analyses using logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 65 patients with a median age of 62.6 years were identified. The median PDC was 93.7%. The frequency of adherence to thalidomide was 56.9%. Adherence to thalidomide showed a negative association with hospitalization in the last 12 months (OR\u2009=\u20090.202; 95% CI\u2009=\u20090.060\u20130.687) and with higher schooling (OR\u2009=0.161; 95% CI\u2009=\u20090.039\u20130.667) and a positive association with higher income (OR\u2009=\u20095.115; 95% CI\u2009=\u20091.363\u201319.190).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Most patients from onco-hematological outpatient clinics in a metropolitan region of southeastern Brazil showed high adherence to thalidomide, which was independently associated with higher income, hospitalization, and higher schooling. More studies are required to understand better the determinants of adherence to thalidomide in the country.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155221993528","type":"journal-article","created":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:35:20Z","timestamp":1613349320000},"page":"373-380","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Adherence to thalidomide in patients with multiple myeloma: A cross-sectional study in a Brazilian metropolis"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8576-6096","authenticated-orcid":false,"given":"L\u00edvia Pena","family":"Silveira","sequence":"first","affiliation":[{"name":"Hospital das Cl\u00ednicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil"},{"name":"Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7083-3188","authenticated-orcid":false,"given":"Cristiane A Menezes de","family":"P\u00e1dua","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula Lana de Miranda","family":"Drummond","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil"},{"name":"Funda\u00e7\u00e3o Ezequiel Dias, Belo Horizonte, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9ssica Soares","family":"Malta","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta M Marques dos","family":"Santos","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Ezequiel Dias, Belo Horizonte, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naiane Lima","family":"Costa","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ta\u00edsa R Lopes","family":"Machado","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas Motta","family":"Hauck","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriano Max Moreira","family":"Reis","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,2,14]]},"reference":[{"key":"bibr1-1078155221993528","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.02.024"},{"key":"bibr2-1078155221993528","doi-asserted-by":"publisher","DOI":"10.1590\/S1516-84842009005000013"},{"key":"bibr3-1078155221993528","first-page":"186","volume":"26","author":"Dashputre AA","year":"2020","journal-title":"J Manag Care Pharm"},{"key":"bibr4-1078155221993528","doi-asserted-by":"publisher","DOI":"10.1177\/1078155213514468"},{"key":"bibr5-1078155221993528","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0214446"},{"key":"bibr6-1078155221993528","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade, Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria. Resolu\u00e7\u00e3o n\u00b0 11, DE 22 DE MAR\u00c7O DE 2011 Disp\u00f5e sobre o controle da subst\u00e2ncia Talidomida e do medicamento que a contenha, http:\/\/bvsms.saude.gov.br\/bvs\/saudelegis\/anvisa\/2011\/res0011_21_03_2011.html (2011, accessed 8 May 2020)."},{"key":"bibr7-1078155221993528","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0405"},{"key":"bibr8-1078155221993528","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.618"},{"key":"bibr9-1078155221993528","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2015.1130710"},{"key":"bibr10-1078155221993528","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4939"},{"key":"bibr11-1078155221993528","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1K671"},{"key":"bibr12-1078155221993528","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00130"},{"key":"bibr13-1078155221993528","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1174"},{"key":"bibr14-1078155221993528","doi-asserted-by":"publisher","DOI":"10.1007\/s13142-015-0315-2"},{"key":"bibr15-1078155221993528","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04167.x"},{"key":"bibr16-1078155221993528","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0543"},{"key":"bibr17-1078155221993528","unstructured":"Campos FT, et al. Thalidomide control and use: are these appropriate to use extension and mitigate the risk of teratogenicity in Brazil? Cien Saude Colet [Published online 2020]. http:\/\/www.cienciaesaudecoletiva.com.br\/en\/articles\/thalidomide-control-and-use-are-these-appropriate-to-use-extension-andmitigate-the-risk-of-teratogenicity-in-brazil\/17698?id=17698&id=17698 (accessed 28 January 2021)."},{"key":"bibr18-1078155221993528","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Secretaria de Aten\u00e7\u00e3o \u00e0 Sa\u00fade. Portaria n\u00b0 708, de 06 de agosto de 2015. Aprova as diretrizes diagn\u00f3sticas e terap\u00eauticas do mieloma m\u00faltiplo. Di\u00e1rio Oficial da Uni\u00e3o, Bras\u00edlia, DF, 2015. Published online \n2015. http:\/\/bvsms.saude.gov.br\/bvs\/saudelegis\/sas\/2015\/prt0708_06_08_2015.html (2015, accessed 8 May 2020)."},{"key":"bibr19-1078155221993528","unstructured":"Xavier FD, Ferreira FSB. DIRETRIZES ONCOL\u00d3GICAS. MIELOMA, https:\/\/diretrizesoncologicas.com.br\/download\/ (2018, accessed 8 May 2020.)"},{"key":"bibr20-1078155221993528","doi-asserted-by":"publisher","DOI":"10.1590\/0102-311X00169514"},{"key":"bibr21-1078155221993528","unstructured":"United Nations. Department of Economic and Social Affairs Population Division. World Population Ageing, www.un.org\/en\/development\/desa\/population\/publications\/ageing\/WorldPopulationAgeing2013.asp (2013, accessed 8 May 2020)."},{"key":"bibr22-1078155221993528","doi-asserted-by":"publisher","DOI":"10.1590\/s1518-8787.2016050006145"},{"key":"bibr23-1078155221993528","first-page":"337","volume":"52","author":"Nunes BP","year":"2018","journal-title":"Rev Sa\u00fade P\u00fab"},{"key":"bibr24-1078155221993528","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-117457"},{"key":"bibr25-1078155221993528","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.e20031"},{"key":"bibr26-1078155221993528","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-020-0182-y"},{"key":"bibr27-1078155221993528","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.03.014"},{"key":"bibr28-1078155221993528","doi-asserted-by":"publisher","DOI":"10.1590\/1980-5497201700040007"},{"key":"bibr29-1078155221993528","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3735-1"},{"key":"bibr30-1078155221993528","first-page":"302","volume":"3","author":"Tomar SK","year":"2019","journal-title":"JPGN Rep"},{"key":"bibr31-1078155221993528","unstructured":"Sweiss K. Oral antimyeloma therapy: barriers to patient adherence and tips for improvement. Hopa News, http:\/\/www.hoparx.org\/hopa-news\/volume-15-issue-3-2018\/oral-antimyeloma-therapy-barriers-to-patient-adherence-and-tips-for-improvement. (2018, accessed 11 May 2020)."},{"issue":"2","key":"bibr32-1078155221993528","first-page":"1","volume":"50","author":"Oliveira MA","year":"2016","journal-title":"Rev Saude Pub"},{"key":"bibr33-1078155221993528","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.2447"},{"key":"bibr34-1078155221993528","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-019-1014-8"},{"key":"bibr35-1078155221993528","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.26.9.1138"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155221993528","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155221993528","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155221993528","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:26:12Z","timestamp":1777688772000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155221993528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,14]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1177\/1078155221993528"],"URL":"https:\/\/doi.org\/10.1177\/1078155221993528","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,14]]}}}